Doxycycline in Type II Diabetes - Trial NCT06329882
Access comprehensive clinical trial information for NCT06329882 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Mostafa Bahaa and is currently Not yet recruiting. The study focuses on Diabetes Mellitus, Type 2. Target enrollment is 60 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Mostafa Bahaa
Tanta University
Timeline & Enrollment
Phase 1/2
Mar 30, 2024
Apr 20, 2025
Primary Outcome
Change in glycemic profile,Change in glycemic profile
Summary
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease characterized by
 hyperglycemia, weight loss, and cardio-metabolic complications. T2DM develops due to the
 progression of insulin resistance (IR), impairment of insulin insensitivity, and failure of
 the pancreatic ฮฒ-cells to release sufficient amount of insulin in response to glucose burden
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06329882
Non-Device Trial